Pemetrexed: all 524 studies that test it

Page 1 of 6. Open to participants first (73), then studies with results posted, then the rest; newest registration first within each.

• MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLCNot yet recruitingNCT07885709Phase 2
• PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50%Not yet recruitingNCT07877584Phase 3
• A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerNot yet recruitingNCT07865910Phase 2/3
• This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.Not yet recruitingNCT07846358Phase 1/2
• A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerNot yet recruitingNCT07822542Phase 3
• A Study of DS-3939a in Participants With Solid TumorsNot yet recruitingNCT07739966Phase 1/2
• Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC PatientsNot yet recruitingNCT07709585Phase 2
• A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung CancerNot yet recruitingNCT07661173Phase 2
• Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS LymphomasNot yet recruitingNCT07608731Phase 1
• BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP DeletionRecruitingNCT07594626Phase 1/2
• SYS6090 Combination Therapy in Advanced Lung CancerNot yet recruitingNCT07472647Phase 1/2
• Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLCRecruitingNCT07405190Phase 2
• Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung CancerNot yet recruitingNCT07229339Phase 2
• Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKIRecruitingNCT07181499Phase 2
• SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLCRecruitingNCT07131319Phase 2/3
• Application of KRAS Vaccine in the Treatment of KRAS-mutated MalignanciesRecruitingNCT07004244Phase 1
• A Platform Study in Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT06996782Phase 1/2
• Evaluation for Healing of Iatrogenic Perforation After Repair With Different MaterialsEnrolling by invitationNCT06976411Phase 4
• A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain MetastasesRecruitingNCT06970639Phase 3
• AK129 Combination Therapy for Advanced Solid TumorsRecruitingNCT06943820Phase 1/2
• Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal MetastasesNot yet recruitingNCT06861218Phase 2
• Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal MetastasisRecruitingNCT06809517Phase 1/2
• Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsRecruitingNCT06772623Phase 1/2
• Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid CancerNot yet recruitingNCT06713057Phase 2
• Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)RecruitingNCT06712316Phase 2/3
• Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid TumorsRecruitingNCT06630416Phase 2
• LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic PatientsRecruitingNCT06576635Not applicable
• Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeMRecruitingNCT06543069Phase 2
• Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal MetastasesNot yet recruitingNCT06537297Phase 2
• Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges MetastaticNot yet recruitingNCT06497543Phase 2
• Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKINot yet recruitingNCT06441045Phase 2
• Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal MetastasesRecruitingNCT06440954Phase 2
• Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung CancerRecruitingNCT06431685Phase 1
• A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC PatientsRecruitingNCT06412471Phase 2
• A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC PatientsNot yet recruitingNCT06335355Phase 2/3
• The Dynamic Monitoring of Cerebrospinal Fluid ctDNARecruitingNCT06315686Phase 2
• Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung CancerRecruitingNCT06304441Not applicable
• Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.RecruitingNCT06296745Phase 2
• Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKIRecruitingNCT06277674Phase 2
• Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCRecruitingNCT06162221Phase 1/2
• A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.Not yet recruitingNCT06142617Phase 2
• A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerRecruitingNCT06119581Phase 3
• Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung CancerNot yet recruitingNCT06109402Phase 2
• Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialRecruitingNCT06096844Phase 3
• A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal MesotheliomaRecruitingNCT06057935Phase 2
• Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib MonotherapyNot yet recruitingNCT06020989Phase 2
• Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung CancerNot yet recruitingNCT05978401Phase 1/2
• Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural MesotheliomaRecruitingNCT05930665Phase 2
• Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLCRecruitingNCT05805631Phase 2
• Dose Attenuated Chemotherapy in Compromised Patients With Lung CancerRecruitingNCT05800587Phase 2
• A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial CancerRecruitingNCT05754853Phase 3
• Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) LymphomasRecruitingNCT05681195Phase 2
• Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung CancerRecruitingNCT05501665Phase 1/2
• First-line Replacement Maintenance of Envafolimab in Advanced NSCLCNot yet recruitingNCT05465733Phase 2
• ATATcH Alternating Treatment Plans for Advanced CancerRecruitingNCT05358548Phase 2
• Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNARecruitingNCT05334277Phase 2
• Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung CancerRecruitingNCT05284539Phase 2
• Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System LymphomaRecruitingNCT05209620Phase 2
• First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural MesotheliomaRecruitingNCT05188859Phase 2
• Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other CancersRecruitingNCT05098132Phase 1/2
• Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerRecruitingNCT05061550Phase 2
• Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint InhibitorsRecruitingNCT05055908Phase 3
• Using ctDNA to Determine Therapies for Lung CancerRecruitingNCT04966663Phase 2
• Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)Not yet recruitingNCT04846634Phase 2
• Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour ResectionEnrolling by invitationNCT04762459Phase 3
• Pemetrexed, Cisplatin With Soft Tissue SarcomaRecruitingNCT04605770Phase 2
• Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLCRecruitingNCT04585490Phase 3
• Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLCRecruitingNCT04322578Phase 2
• Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/ImmunotherapyRecruitingNCT04253964Phase 2
• Pan Tumor Rollover StudyRecruitingNCT03899155Phase 2
• Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLCRecruitingNCT03872661Phase 2
• Adjuvant Chemotherapy for High Risk Stage I Lung AdenocarcinomaRecruitingNCT03380468Phase 2/3
• Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%RecruitingNCT03351842Phase 2
• A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic CancerTerminatedNCT06630325Phase 2Results posted
• A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 GeneTerminatedNCT05469178Phase 1/2Results posted
• Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung CancerTerminatedNCT04971187Phase 2Results posted
• Pembrolizumab With Standard Cytotoxic Chemotherapy in Treatment Naive NSCLC Patients With Asymptomatic Brain MetastasesCompletedNCT04967417Phase 2Results posted
• Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLCTerminatedNCT04524689Phase 2Results posted
• Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated PatientsTerminatedNCT04512430Phase 2Results posted
• A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung CancerActive, not recruitingNCT04351555Phase 3Results posted
• ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung CarcinomaCompletedNCT04245085Phase 2Results posted
• Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung CancerCompletedNCT04205812Phase 3Results posted
• Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLCTerminatedNCT04163432Phase 2Results posted
• A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)CompletedNCT04153565Phase 1Results posted
• A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted TherapiesCompletedNCT04042558Phase 2Results posted
• A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)Active, not recruitingNCT04035486Phase 3Results posted
• Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung CancerTerminatedNCT03737994Phase 2Results posted
• Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung CancerTerminatedNCT03713944Phase 2Results posted
• Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung CancerTerminatedNCT03559049Phase 1/2Results posted
• Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung CancerTerminatedNCT03366766Phase 2Results posted
• A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)TerminatedNCT03337698Phase 1/2Results posted
• Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLCCompletedNCT03256136Phase 2Results posted
• Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant MesotheliomaActive, not recruitingNCT03228537Phase 1Results posted
• A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02998528Phase 3Results posted
• A Study of Pemetrexed in Recurrent Cervical AdenocarcinomasTerminatedNCT02868892Phase 2Results posted
• A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) TherapyCompletedNCT02864251Phase 3Results posted
• Pembrolizumab in Patients With Advanced Malignant Pleural MesotheliomaCompletedNCT02784171Phase 2/3Results posted
• Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and CisplatinCompletedNCT02709512Phase 2/3Results posted
• Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial CancerTerminatedNCT02693717Phase 2Results posted
• 2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast CancerTerminatedNCT02624700Phase 2Results posted

← Pemetrexed overview